Literature DB >> 25478368

Evaluation and comparison of anticonvulsant activity of telmisartan and olmesartan in experimentally induced animal models of epilepsy.

Pushpa V H1, Padmaja Shetty K2, Suresha R N3, Jayanthi M K3, Ashwini V2, Vaibhavi P S2.   

Abstract

BACKGROUND: Epilepsy is one common neurological disorder requiring newer targets and newer drugs for its efficient management. In the recent days brain renin angiotensin system has gained immense importance because of its involvement in seizure regulation.
OBJECTIVE: To evaluate and compare antiepileptic activity of different doses olmesartan and telmisartan on MES and PTZ induced seizure models.
MATERIALS AND METHODS: Swiss albino mice weighing around 25-30g of either sex were divided into 6 groups: Control ( Distilled Water- 10ml/kg), Standard - Sodium valproate (40mg/kg), O1 - Olmesartan (2.5mg/kg), O2 - Olmesartan (5mg/kg), T1 - Telmisartan (5mg/kg), T2 - Telmisartan (10mg/kg). After 1hour of administration of control , test and standard drugs (orally), convulsions were induced by administering PTZ (70mg/kg - i.p.) in PTZ model. Seizure latency was the parameter recorded. In MES model, suppression of tonic hind limb extension was taken as measure of efficacy. RESULT: The results were analysed by one-way-ANOVA followed by Bonferroni's multiple comparison test. In MES test, dose dependently olmesartan and telmisartan significantly reduced the duration of tonic hindlimb extension in comparison to control (p<0.05). T2 - 9 + 0.89secs significantly reduced the tonic hind limb extension compared to other test groups (p<0.05). The percentage inhibition of seizure was T2-44.3%, O2-28.2%, T1-17.5%, O1- 12.3% respectively. In PTZ test, dose dependently olmesartan and telmisartan produced significant increase in seizure latency (p<0.05). T2 - 206.6+9.83secs significantly increased seizure latency compared to other test groups (p<0.05). Percentage protection from seizure is T2-52.6%, O2- 45.13%, T1- 37.5%, O1- 38.4% respectively.
CONCLUSION: AT1 receptor antagonist, telmisartan and olmesartan in a dose dependent manner showed increase in antiepileptic activity. Temisartan at higher dose produced significant antiepileptic activity in comparison to olmesartan.

Entities:  

Keywords:  AT1 Receptor; Antiepileptic activity; MES model; Olmesartan; PTZ Model; Telmisartan

Year:  2014        PMID: 25478368      PMCID: PMC4253186          DOI: 10.7860/JCDR/2014/9455.5061

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  12 in total

1.  Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress.

Authors:  Enrique Sánchez-Lemus; Masaru Honda; Juan M Saavedra
Journal:  Behav Brain Res       Date:  2012-04-04       Impact factor: 3.332

2.  The effects of chronic losartan pretreatment on restraint stress-induced changes in motor activity, nociception and pentylenetetrazol generalized seizures in rats.

Authors:  Daniela M Pechlivanova; Alexander G Stoynev; Jana D Tchekalarova
Journal:  Folia Med (Plovdiv)       Date:  2011 Apr-Jun

3.  Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.

Authors:  Krzysztof Łukawski; Agnieszka Janowska; Tomasz Jakubus; Anna Tochman-Gawda; Stanisław J Czuczwar
Journal:  Eur J Pharmacol       Date:  2010-05-11       Impact factor: 4.432

4.  Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion.

Authors:  X Wu; T Kihara; H Hongo; A Akaike; T Niidome; H Sugimoto
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

5.  Effects of seizures and antiepileptic drugs on benzodiazepine receptors in rat brain.

Authors:  T Mimaki; H Yabuuchi; H Laird; H I Yamamura
Journal:  Pediatr Pharmacol (New York)       Date:  1984

6.  Angiotensin II inhibits GABAergic synaptic transmission in dorsolateral periaqueductal gray neurons.

Authors:  Jihong Xing; Jian Lu; Jianhua Li
Journal:  Neurosci Lett       Date:  2009-03-24       Impact factor: 3.046

7.  Interactions between angiotensin AT1 receptor antagonists and second-generation antiepileptic drugs in the test of maximal electroshock.

Authors:  Krzysztof Łukawski; Agnieszka Janowska; Tomasz Jakubus; Stanisław J Czuczwar
Journal:  Fundam Clin Pharmacol       Date:  2013-03-28       Impact factor: 2.748

8.  Combined treatment with gabapentin and drugs affecting the renin-angiotensin system against electroconvulsions in mice.

Authors:  Krzysztof Lukawski; Agnieszka Janowska; Tomasz Jakubus; Grzegorz Raszewski; Stanisław J Czuczwar
Journal:  Eur J Pharmacol       Date:  2013-03-13       Impact factor: 4.432

Review 9.  The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers.

Authors:  J Culman; A Blume; P Gohlke; T Unger
Journal:  J Hum Hypertens       Date:  2002-08       Impact factor: 3.012

10.  Renin-Angiotensin system and sympathetic neurotransmitter release in the central nervous system of hypertension.

Authors:  Kazushi Tsuda
Journal:  Int J Hypertens       Date:  2012-11-21       Impact factor: 2.420

View more
  3 in total

Review 1.  The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.

Authors:  Natasha Ivanova; Jana Tchekalarova
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

2.  Telmisartan reduced cerebral edema by inhibiting NLRP3 inflammasome in mice with cold brain injury.

Authors:  Xin Wei; Chen-Chen Hu; Ya-Li Zhang; Shang-Long Yao; Wei-Ke Mao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

Review 3.  Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It.

Authors:  Aswar Urmila; Patil Rashmi; Ghag Nilam; Bodhankar Subhash
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-11-30       Impact factor: 1.636

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.